Quent Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.9K Sell
737
-37
-5% -$1.71K ﹤0.01% 994
2026
Q2
$37.1K Buy
774
+48
+7% +$2.06K ﹤0.01% 894
2026
Q1
$26.7K Sell
726
-144
-17% -$6.82K ﹤0.01% 904
2025
Q4
$44.3K Buy
870
+144
+20% +$7.36K ﹤0.01% 778
2025
Q3
$40.3K Buy
+726
New +$42.5K ﹤0.01% 663
2025
Q2
– Sell
-726
Closed -$50.4K – 929
2025
Q1
$50.4K Hold
726
– – 0.01% 559
2024
Q4
$62.5K Buy
+726
New +$78.5K 0.01% 529

Other funds holding NVO

Quent Capital's NVO Position: Q3 2026 in Review

Quent Capital reduced its Novo Nordisk (NVO) stake by 4.8% in Q3 2026, selling an estimated $1.71K and leaving 737 shares worth $27.9K. The position accounts for ﹤0.01% of the portfolio, ranked #994.

Quent Capital first reported a position in NVO in Q4 2024 and has held it in 7 quarters since. The position peaked at $62.5K in Q4 2024. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Quent Capital held 737 shares of Novo Nordisk worth $27.9K as of Q3 2026.
  • Quent Capital sold 37 Novo Nordisk shares in Q3 2026, an estimated $1.71K.
  • Novo Nordisk made up ﹤0.01% of Quent Capital's portfolio in Q3 2026, its #994 holding.
  • Quent Capital first reported a position in Novo Nordisk in Q4 2024 and has held it in 7 quarters since.
  • Quent Capital's Novo Nordisk position peaked at $62.5K in Q4 2024.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Quent Capital's 13F filing for Q3 2026, filed 9 Nov 2026.